期刊： ANNALS OF HEMATOLOGY, 2022; 101 (1)
Despite the effectiveness of plasma exchange (PEX) and immunosuppressants in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a n......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (2)
Persistent thrombocytopenia (PT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of bleeding......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (10)
Relapse and refractoriness remain the major obstacles in clinical treatment of acute myeloid leukemia (AML). Efficacy of current therapeutic strategie......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (10)
Tyrosine kinase inhibitors (TKIs) have dramatically changed the way chronic myeloid leukemia (CML) is treated. Although TKI therapy improves the overa......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (11)
Multiple myeloma (MM) patients are predominantly elderly with comorbidities that have an impact on patient mortality and treatment decisions. We previ......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
To investigate the pathogenesis and the refractory/relapse mechanisms in patients with t(16;21)(p11;q22), we retrospectively analyzed the clinical dat......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
Hetrombopag is the only CFDA-approved thrombopoietin (TPO) receptor agonist for severe aplastic anemia (SAA) in China. Its chemical structure has an i......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
Mutations in myelodysplasia-related (MR) genes, rather than morphological features, have been included in the diagnostic criteria of the new 5th World......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (12)
Molecular diagnostics moves more into focus as technology advances. In patients with myeloproliferative neoplasms (MPN), identification and monitoring......
期刊： ANNALS OF HEMATOLOGY, 2022; 101 (2)
Chronic lymphocytic leukemia (CLL) is the most common mature B-cell neoplasm in the West. IGHV4-34 is one of the most frequently used genes in CLL pat......
